Stock SAVA CASSAVA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
22.3 USD -0.18% Intraday chart for Cassava Sciences, Inc. +8.52% -0.93%
Apr. 29 North American Morning Briefing : Investors Brace -2- DJ
Mar. 25 Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam
MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials
CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia
CI
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease
CI
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients
CI
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer?s Disease
CI
Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer?s Disease
CI
Cassava Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study
CI
Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging
CI
Cassava Sciences Completes Patient Dosing in A Randomized Controlled Trial of Simufilam in Alzheimer’S Disease
CI
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Cassava Sciences Posts Wider Q4 Loss
MT
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
CI
Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAVA Stock
  4. News Cassava Sciences, Inc.
  5. Highlights